Central nervous system lymphoma: Characteristic findings on traditional and advanced imaging

American Journal of Neuroradiology

Volumn 32, Issue 6, 2011, Pages 984-992

  Haldorsen, Ingfrid S ^a,b   Espeland, A ^a,b   Larsson, E M ^c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; FLUORODEOXYGLUCOSE; IOFETAMINE I 123; LIPID; METHIONINE C 11; PROTON; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; THALLIUM 201;

BASAL GANGLION; BLOOD VESSEL PERMEABILITY; BRAIN BIOPSY; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN METASTASIS; BRAIN STEM; CANCER DIAGNOSIS; CANCER INFILTRATION; CANCER LOCALIZATION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CEREBELLUM; COMMUNICATING HYDROCEPHALUS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRANIAL NERVE; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE DURATION; FRONTAL LOBE; GLIOMA; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INTRACRANIAL HYPERTENSION; INTRAOCULAR LYMPHOMA; INTRAOCULAR TUMOR; LYMPHOMA; MENINGEAL METASTASIS; MICROVASCULATURE; NEUROIMAGING; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; REVIEW; SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLIT LAMP; SPINAL CORD; SPINAL CORD TUMOR; SPINAL ROOT; SUBVENTRICULAR ZONE; SUSCEPTIBILITY WEIGHTED IMAGING; SYSTEMIC DISEASE; TUMOR VASCULARIZATION; WHITE MATTER;

BRAIN NEOPLASMS; HUMANS; IMAGE ENHANCEMENT; LYMPHOMA; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79959300086     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2171     Document Type: Review

References (66)

1. Wong ET. Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities. Clin Cancer Res 2005;11:7151s-57s
2. Mohile NA, Abrey LE. Primary central nervous system lymphoma. Semin Radiat Oncol 2007;17:223-29 (Pubitemid 46963033)
3. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006;20:319-32 (Pubitemid 44691999)
4. Montoto S, Lister TA. Secondary central nervous system lymphoma: risk factors and prophylaxis. Hematol Oncol Clin North Am 2005;19:751-63 (Pubitemid 41096718)
5. Haldorsen IS, Krossnes BK, Aarseth JH, et al. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003: time trends in a 15-year national survey. Cancer 2007;110:1803-14
6. van der Sanden GA, Schouten LJ, van Dijck JA, et al. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer 2002;94:1548-56 (Pubitemid 34212650)
7. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504-10
8. Cote TR, Manns A, Hardy CR, et al. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome: AIDS/Cancer Study Group. J Natl Cancer Inst 1996;88:675-79 (Pubitemid 26152554)
9. Kasamon YL, Ambinder RF. AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005;19:665-87 (Pubitemid 41096712)
10. Diamond C, Taylor TH, Aboumrad T, et al. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006;106:128-35 (Pubitemid 43032557)
11. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-44
12. Haldorsen IS, Espeland A, Larsen JL, et al. Diagnostic delay in primary central nervous system lymphoma. Acta Oncol 2005;44:728-34 (Pubitemid 41547074)
13. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009;8:581-92
14. Haldorsen IS, Krakenes J, Krossnes BK, et al. CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003. AJNR Am J Neuroradiol 2009;30:744-51
15. Buhring U, Herrlinger U, Krings T, et al. MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393-96 (Pubitemid 32757581)
16. Senocak E, Oguz KK, Ozgen B, et al. Parenchymal lymphoma of the brain on initial MR imaging: a comparative study between primary and secondary brain lymphoma. Eur J Radiol 2010 Mar 2. [Epub ahead of print]
17. Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2005;19:597-609 (Pubitemid 41096708)
18. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest 2005;23:145-54 (Pubitemid 40463913)
19. van Oostenbrugge RJ, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 1999;53:382-85 (Pubitemid 29344363)
20. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-57
21. Gleissner B, Chamberlain M. Treatment of CNS dissemination in systemic lymphoma. J Neurooncol 2007;84:107-17 (Pubitemid 47103452)
22. Fitzsimmons A, Upchurch K, Batchelor T. Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005;19:689-703 (Pubitemid 41096713)
23. Eichler AF, Batchelor TT. Primary central nervous system lymphoma: presentation, diagnosis and staging. Neurosurg Focus 2006;21:E15
24. Koeller KK, Smirniotopoulos JG, Jones RV. Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics 1997;17:1497-526 (Pubitemid 127466070)
25. GoJL, Lee SC, Kim PE. Imaging of primary central nervous system lymphoma. Neurosurg Focus 2006;21:E4
26. Gliemroth J, Kehler U, Gaebel C, et al. Neuroradiological findings in primary cerebral lymphomas of non-AIDS patients. Clin Neurol Neurosurg 2003;105:78-86 (Pubitemid 36411671)
27. Coulon A, Lafitte F, Hoang-Xuan K, et al. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol 2002;12:329-40 (Pubitemid 36940068)
28. ThurnherMM,Rieger A, Kleibl-Popov C, et al. Primary central nervous system lymphoma in AIDS: a wider spectrum ofCTandMRIfindings. Neuroradiology 2001;43:29-35 (Pubitemid 32123964)
29. Kuker W, Nagele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005;72:169-77 (Pubitemid 40796468)
30. Weaver JD, Vinters HV, Koretz B, et al. Lymphomatosis cerebri presenting as rapidly progressive dementia. Neurologist 2007;13:150-53 (Pubitemid 46743083)
31. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-104 (Pubitemid 23359924)
32. Hayakawa T, Takakura K, Abe H, et al. Primary central nervous system lymphoma in Japan: a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol 1994;19:197-215 (Pubitemid 24296628)
33. Schlegel U, Schmidt-Wolf IG, Deckert M. Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000;181:1-12
34. Erdag N, Bhorade RM, Alberico RA, et al. Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. AJR Am J Roentgenol 2001;176:1319-26 (Pubitemid 32323282)
35. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000;92:261-66 (Pubitemid 30071045)
36. Gunduz K, Pulido JS, McCannel CA, et al. Ocular manifestations and treatment of central nervous system lymphomas. Neurosurg Focus 2006;21:E9
37. Kuker W, Herrlinger U, Gronewaller E, et al. Ocular manifestation of primary nervous system lymphoma: what can be expected from imaging? J Neurol 2002;249:1713-16
38. Iwamoto FM, Abrey LE. Primary dural lymphomas: a review. Neurosurg Focus 2006;21:E5
39. Haldorsen IS, Krakenes J, Goplen AK, et al. AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003. BMC Cancer 2008;8:225
40. Calli C, Kitis O, Yunten N, et al. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006;58:394-403 (Pubitemid 43729064)
41. Hartmann M, Heiland S, Harting I, et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 2003;338:119-22 (Pubitemid 36140152)
42. Harting I, Hartmann M, Jost G, et al. Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett 2003;342:163-66 (Pubitemid 36570343)
43. Taillibert S, Guillevin R, Menuel C, et al. Brain lymphoma: usefulness of the magnetic resonance spectroscopy. J Neurooncol 2008;86:225-29 (Pubitemid 350263422)
44. Zacharia TT, Law M, Naidich TP, et al. Central nervous system lymphoma characterization by diffusion-weighted imaging andMRspectroscopy. J Neuroimaging 2008;18:411-17
45. Schroeder PC, Post MJ, Oschatz E, et al. Analysis of the utility of diffusion-weighted MRI and apparent diffusion coefficient values in distinguishing central nervous system toxoplasmosis from lymphoma. Neuroradiology 2006;48:715-20 (Pubitemid 44490048)
46. Stadnik TW, Chaskis C, Michotte A, et al. Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 2001;22:969-76 (Pubitemid 32436243)
47. Toh CH, Castillo M, Wong AM, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 2008;29:471-75 (Pubitemid 351424059)
48. Barajas RF Jr, Rubenstein JL, Chang JS, et al. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2010;31:60-66. Epub 2009 Sep 3
49. Wu O, Ostergaard L, Sorensen AG. Technical aspects of perfusion-weighted imaging. Neuroimaging Clin N Am 2005;15:623-37, xi
50. Cianfoni A, Colosimo C, Basile M, et al. Brain perfusion CT: principles, technique and clinical applications. Radiol Med 2007;112:1225-43
51. Fainardi E, Di BF, Borrelli M, et al. Potential role of CT perfusion parameters in the identification of solitary intra-axial brain tumor grading. Acta Neurochir Suppl 2010;106:283-87
52. Hakyemez B, Erdogan C, Bolca N, et al. Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. J Magn Reson Imaging 2006;24:817-24 (Pubitemid 44549984)
53. Larsson HB, Courivaud F, Rostrup E, et al. Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 Tesla. Magn Reson Med 2009;62:1270-81
54. Kim HS, Jahng GH, Ryu CW, et al. Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol 2009;30:1574-79
55. Peng XH, Qian X, Mao H, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine 2008;3:311-21
56. Manninger SP, Muldoon LL, Nesbit G, et al. An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. AJNR Am J Neuroradiol 2005;26:2290-300
57. Bakshi R. Neuroimaging of HIV and AIDS related illnesses: a review. Front Biosci 2004;9:632-46 (Pubitemid 39043740)
58. Chang L, Ernst T. MR spectroscopy and diffusion-weighted MR imaging in focal brain lesions in AIDS. Neuroimaging Clin N Am 1997;7:409-26 (Pubitemid 27434580)
59. Chang L, Miller BL, McBride D, et al. Brain lesions in patients with AIDS: H-1 MR spectroscopy. Radiology 1995;197:525-31
60. Palmedo H, Urbach H, Bender H, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006;33:164-68 (Pubitemid 43152883)
61. Rosenfeld SS, Hoffman JM, Coleman RE, et al. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992;33:532-36
62. Ogawa T, Kanno I, Hatazawa J, et al. Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. Radiographics 1994;14:101-10
63. Shinoda J, Yano H, Murase S, et al. High 123I-IMP retention on SPECT image in primary central nervous system lymphoma. J Neurooncol 2003;61:261-65 (Pubitemid 36342305)
64. Ruiz A, Ganz WI, Post MJ, et al. Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. AJNR Am J Neuroradiol 1994;15:1885-94 (Pubitemid 24352834)
65. Chen W, Silverman DH. Advances in evaluation of primary brain tumors. Semin Nucl Med 2008;38:240-50 (Pubitemid 351726325)
66. Heiss WD. The potential of PET/MR for brain imaging. Eur J Nucl Med Mol Imaging 2009;36(suppl 1):S105-12